{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T13:54:32Z","timestamp":1785678872804,"version":"3.56.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:p>Epithelioid mesothelioma with a solid histologic pattern (solid epithelioid mesothelioma) is difficult to distinguish from a poorly differentiated squamous cell lung carcinoma and\/or solid lung adenocarcinoma. Thus, immunohistochemical markers are essential for diagnosis; however, the sensitivity and specificity of pre-existing mesothelial markers are suboptimal, particularly for differentiation from squamous cell carcinoma. Using a cancer-dependency map, we analyzed gene expression data of pleural mesothelioma and non\u2013small cell lung cancer cell lines (squamous cell carcinoma and adenocarcinoma) and identified secreted protein acidic and cysteine-rich (SPARC) as a promising candidate for the differential diagnosis of epithelioid mesothelioma from lung squamous cell carcinoma and\/or lung adenocarcinoma. SPARC expression in mesothelioma and lung cancer cell lines was validated using reverse-transcription polymerase chain reaction, western blotting, and immunohistochemistry. Immunohistochemical staining was performed using anti-SPARC antibodies against solid epithelioid mesothelioma, solid lung adenocarcinoma, and poorly differentiated lung squamous cell carcinoma. SPARC positivity was seen in 42\/45 (93.3%) of solid epithelioid mesothelioma, 2\/40 (5%) solid lung adenocarcinoma, and 2\/45 (4.5%) of lung squamous cell carcinomas. The sensitivity, specificity, and diagnostic accuracy for differentiating solid epithelioid mesothelioma from lung cancer (solid lung adenocarcinoma and poorly differentiated lung squamous cell carcinoma) were 93.3, 95.2, and 94.6%, respectively. In conclusion, SPARC is a novel mesothelial marker that can be used to differentiate epithelioid mesothelioma from squamous cell carcinoma and lung adenocarcinoma.<\/jats:p>","DOI":"10.1097\/pas.0000000000002147","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T05:00:09Z","timestamp":1698642009000},"page":"140-149","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["SPARC Is a Novel Positive Immunohistochemical Marker of Epithelioid Mesothelioma to Differentiate It From Lung Adenocarcinoma and\/or Squamous Cell Carcinoma"],"prefix":"10.1097","volume":"48","author":[{"given":"Tetsuya","family":"Nakagiri","sequence":"first","affiliation":[{"name":"Department of Pathology, Graduate School of Biomedical and Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishwa J.","family":"Amatya","sequence":"additional","affiliation":[{"name":"Department of Pathology, Graduate School of Biomedical and Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Kushitani","sequence":"additional","affiliation":[{"name":"Department of Pathology, Graduate School of Biomedical and Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kambara","sequence":"additional","affiliation":[{"name":"Department of Pathology, Graduate School of Biomedical and Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Aoe","sequence":"additional","affiliation":[{"name":"Department of Pathology, Graduate School of Biomedical and Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ihiro","family":"Endo","sequence":"additional","affiliation":[{"name":"Department of Pathology, Graduate School of Biomedical and Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Miyata","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Research Center for Radiation Casualty Medicine, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morihito","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Research Center for Radiation Casualty Medicine, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Takeshima","sequence":"additional","affiliation":[{"name":"Department of Pathology, Graduate School of Biomedical and Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,10,30]]},"reference":[{"key":"R1-20250608","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajim.20246","article-title":"Estimation of future mortality from pleural malignant mesothelioma in Japan based on an age-cohort model","volume":"49","author":"Murayama","year":"2006","journal-title":"Am J Ind Med"},{"key":"R2-20250608","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1046\/j.1365-2559.2003.01674.x","article-title":"\u2018Pseudomesotheliomatous\u2019 carcinomas of the pleura: a 10-year analysis of cases from the Environmental Lung Disease Research Group, Cardiff: Pleural \u2018pseudomesotheliomas.\u2019","volume":"43","author":"Attanoos","year":"2003","journal-title":"Histopathology"},{"key":"R4-20250608","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/his.13073","article-title":"Utility and pitfalls of immunohistochemistry in the differential diagnosis between epithelioid mesothelioma and poorly differentiated lung squamous cell carcinoma","volume":"70","author":"Kushitani","year":"2017","journal-title":"Histopathology"},{"key":"R5-20250608","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1097\/PAS.0000000000001469","article-title":"HEG1 is a highly specific and sensitive marker of epithelioid malignant mesothelioma","volume":"44","author":"Naso","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"R6-20250608","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1097\/PAS.0000000000000852","article-title":"Identification of DAB2 and intelectin-1 as novel positive immunohistochemical markers of epithelioid mesothelioma by transcriptome microarray analysis for its differentiation from pulmonary adenocarcinoma","volume":"41","author":"Kuraoka","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"R7-20250608","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/modpathol.2017.190","article-title":"Glypican-1 immunohistochemistry is a novel marker to differentiate epithelioid mesothelioma from lung adenocarcinoma","volume":"31","author":"Amatya","year":"2018","journal-title":"Mod Pathol"},{"key":"R8-20250608","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1097\/PAS.0000000000001507","article-title":"SOX6 is a novel immunohistochemical marker for differential diagnosis of epithelioid mesothelioma from lung adenocarcinoma","volume":"44","author":"Kambara","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"R9-20250608","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5858\/arpa.2017-0124-RA","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma: 2017 update of the consensus statement from the international mesothelioma interest group","volume":"142","author":"Husain","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"R10-20250608","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41598-017-18545-x","article-title":"MUC4 immunohistochemistry is useful in distinguishing epithelioid mesothelioma from adenocarcinoma and squamous cell carcinoma of the lung","volume":"8","author":"Mawas","year":"2018","journal-title":"Sci Rep"},{"key":"R11-20250608","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1172\/JCI12939","article-title":"SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury","volume":"107","author":"Bradshaw","year":"2001","journal-title":"J Clin Invest"},{"key":"R12-20250608","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.biocel.2011.12.021","article-title":"Diverse biological functions of the SPARC family of proteins","volume":"44","author":"Bradshaw","year":"2012","journal-title":"Int J Biochem Cell Biol"},{"key":"R13-20250608","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/jcb.20091","article-title":"SPARC and tumor growth: where the seed meets the soil?","volume":"92","author":"Framson","year":"2004","journal-title":"J Cell Biochem"},{"key":"R14-20250608","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bph.13653","article-title":"The SPARC protein: an overview of its role in lung cancer and pulmonary fibrosis and its potential role in chronic airways disease","volume":"174","author":"Wong","year":"2017","journal-title":"Br J Pharmacol"},{"key":"R15-20250608","first-page":"5376","article-title":"Enhanced expression of SPARC\/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia\/ acidity and with poor prognosis of patients","volume":"63","author":"Koukourakis","year":"2003","journal-title":"Cancer Res"},{"key":"R16-20250608","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.lungcan.2004.01.020","article-title":"Increased osteonectin expression is associated with malignant transformation and tumor associated fibrosis in the lung","volume":"45","author":"Siddiq","year":"2004","journal-title":"Lung Cancer"},{"key":"R17-20250608","first-page":"541","article-title":"SPARC expression and prognostic value in non-small cell lung cancer","volume":"31","author":"Huang","year":"2012","journal-title":"Chin J Cancer"},{"key":"R18-20250608","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/s41598-022-04973-x","article-title":"A panel of emerging EMT genes identified in malignant mesothelioma","volume":"12","author":"Wu","year":"2022","journal-title":"Sci Rep"},{"key":"R19-20250608","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/cjp2.218","article-title":"High tumor cell platelet-derived growth factor receptor beta expression is associated with shorter survival in malignant pleural epithelioid mesothelioma","volume":"7","author":"Ollila","year":"2021","journal-title":"J Pathol Clin Res"},{"key":"R20-20250608","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/bjc.2015.470","article-title":"A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma","volume":"114","author":"Kao","year":"2016","journal-title":"Br J Cancer"},{"key":"R21-20250608","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2012.05.014","article-title":"Application of immunohistochemistry in the diagnosis of epithelioid mesothelioma: a review and update","volume":"44","author":"Ord\u00f3\u00f1ez","year":"2013","journal-title":"Human Pathology"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002147","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T20:03:40Z","timestamp":1749413020000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,30]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000002147","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,30]]}}}